NO20022835L - Substituerte imidazol neuropeptid Y Y5 reseptorantagonister - Google Patents

Substituerte imidazol neuropeptid Y Y5 reseptorantagonister

Info

Publication number: NO20022835L
Authority: NO; Norway
Prior art keywords: neuropeptide; receptor antagonists; substituted imidazole; imidazole; substituted
Prior art date: 1999-12-16

Application number

NO20022835A

Other languages

English (en)

Norwegian (no)

Other versions

NO20022835D0 (no

Inventor

Andrew W Stamford

Craig D Boyle

Ying Huang

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-16

Filing date

2002-06-14

Publication date

2002-08-16

2002-06-14 Application filed by Schering Corp filed Critical Schering Corp

2002-06-14 Publication of NO20022835D0 publication Critical patent/NO20022835D0/no

2002-08-16 Publication of NO20022835L publication Critical patent/NO20022835L/no

Links

RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 2
101710151321 Melanostatin Proteins 0.000 title 1
102400000064 Neuropeptide Y Human genes 0.000 title 1
102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 title 1
101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 title 1
150000002460 imidazoles Chemical class 0.000 title 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20022835A 1999-12-16 2002-06-14 Substituerte imidazol neuropeptid Y Y5 reseptorantagonister NO20022835L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17122399P	1999-12-16	1999-12-16
PCT/US2000/033832 WO2001044201A1 (fr)	1999-12-16	2000-12-14	Antagonistes du recepteur y5 au neuropeptide y a imidazoles substituees

Publications (2)

Publication Number	Publication Date
NO20022835D0 NO20022835D0 (no)	2002-06-14
NO20022835L true NO20022835L (no)	2002-08-16

Family

ID=22622991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022835A NO20022835L (no)	1999-12-16	2002-06-14	Substituerte imidazol neuropeptid Y Y5 reseptorantagonister

Country Status (26)

Country	Link
US (2)	US6444687B1 (fr)
EP (1)	EP1237875B1 (fr)
JP (2)	JP4180276B2 (fr)
KR (1)	KR20020062342A (fr)
CN (1)	CN1227236C (fr)
AR (1)	AR032292A1 (fr)
AT (1)	ATE303364T1 (fr)
AU (1)	AU2261401A (fr)
BR (1)	BR0017025A (fr)
CA (1)	CA2393821C (fr)
CZ (1)	CZ20022100A3 (fr)
DE (1)	DE60022386T2 (fr)
ES (1)	ES2243337T3 (fr)
HK (1)	HK1045503A1 (fr)
HU (1)	HUP0301218A2 (fr)
IL (1)	IL149872A0 (fr)
MX (1)	MXPA02006016A (fr)
MY (1)	MY138524A (fr)
NO (1)	NO20022835L (fr)
NZ (1)	NZ519272A (fr)
PL (1)	PL356485A1 (fr)
RU (1)	RU2002119019A (fr)
SK (1)	SK8452002A3 (fr)
TR (1)	TR200201568T2 (fr)
WO (1)	WO2001044201A1 (fr)
ZA (1)	ZA200204350B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6989379B1 (en)	1999-04-22	2006-01-24	H. Lundbick A/S	Selective NPY (Y5) antagonists
US6340683B1 (en)	1999-04-22	2002-01-22	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (triazines)
DK1183245T3 (da)	1999-04-22	2007-09-24	Lundbeck & Co As H	Selektive NPY(Y5)-antagonister
CA2380866A1 (fr) *	1999-06-30	2001-01-11	Synaptic Pharmaceutical Corporation	Antagonistes selectifs du npy (y5)
US7273880B2 (en)	1999-06-30	2007-09-25	H. Lunbeck A/S	Selective NPY (Y5) antagonists
DE10035908A1 (de) *	2000-07-21	2002-03-07	Asta Medica Ag	Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
FR2818978B1 (fr) *	2000-12-28	2003-02-28	Sod Conseils Rech Applic	Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
FR2825926A1 (fr)	2001-06-14	2002-12-20	Sod Conseils Rech Applic	Derives d'imidazoles modulant les canaux sodiques
WO2003000249A1 (fr) *	2001-06-26	2003-01-03	Takeda Chemical Industries, Ltd.	Regulateur de la fonction du recepteur relatif aux retinoides
WO2003022820A1 (fr) *	2001-09-06	2003-03-20	Bristol-Myers Squibb Pharma Company.	Cyclopropane hetero-aromatique substitue utilise comme hormone adrenocorticotrope
CA2403307A1 (fr)	2001-10-23	2003-04-23	Neurogen Corporation	Derives de l'imidazole 2-cyclohexyl-4-phenyl-1h substitue
BR0307429A (pt) *	2002-02-05	2004-12-28	Novo Nordisk As	Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
RU2361869C2 (ru) *	2002-02-05	2009-07-20	ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Новые арил- и гетероарилпиперазины
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
FR2846655B1 (fr) *	2002-11-05	2004-12-24	Servier Lab	Nouveaux derives de la pyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7332508B2 (en)	2002-12-18	2008-02-19	Novo Nordisk A/S	Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
CA2514363A1 (fr) *	2003-02-12	2004-08-26	Transtech Pharma, Inc.	Utilisation de derives d'azoles substitues en tant qu'agents therapeutiques
FR2855520B1 (fr) *	2003-05-27	2007-06-29	Sod Conseils Rech Applic	Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
CN1795179A (zh) *	2003-05-27	2006-06-28	科学研究和应用咨询公司	新的咪唑衍生物、其制备方法和其作为药物的用途
CN1902177A (zh)	2003-09-22	2007-01-24	万有制药株式会社	新哌啶衍生物
EP2305352A1 (fr)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
WO2006004142A1 (fr) *	2004-06-30	2006-01-12	Banyu Pharmaceutical Co., Ltd.	Dérivés de biaryles
WO2006044502A2 (fr) *	2004-10-13	2006-04-27	Ptc Therapeutics, Inc.	Composes pour la suppression de mutations non-sens et procedes d'utilisation associes
AU2005295752A1 (en) *	2004-10-15	2006-04-27	Amgen Inc.	Imidazole derivatives as vanilloid receptor ligands
BRPI0518241A (pt)	2004-11-01	2008-04-22	Amylin Pharmaceuticals Inc	métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
TW200633990A (en)	2004-11-18	2006-10-01	Takeda Pharmaceuticals Co	Amide compound
AU2006235200A1 (en) *	2005-04-15	2006-10-19	Regenertech Pty Limited	Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
GB0510141D0 (en) *	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B3
CA2609388C (fr)	2005-05-30	2013-08-06	Banyu Pharmaceutical Co., Ltd.	Nouveau derive de piperidine
RU2444516C2 (ru) *	2005-06-29	2012-03-10	Янссен Фармацевтика Нв	Способ синтеза производных имидазоламинокислот и родственных соединений
EP2233470B1 (fr)	2005-07-04	2011-12-07	High Point Pharmaceuticals, LLC	Antagonists du receptor histamine H3
US20100216758A1 (en)	2005-08-10	2010-08-26	Makoto Ando	Pyridone Compounds
EP2330125A3 (fr)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Polypeptides hybrides ayant des propriétés sélectionnables
EP1922336B1 (fr)	2005-08-11	2012-11-21	Amylin Pharmaceuticals, LLC	Polypeptides hybrides presentant des proprietes selectionnables
WO2007024004A1 (fr)	2005-08-24	2007-03-01	Banyu Pharmaceutical Co., Ltd.	Dérivé phénylpyridone
EP1939194A4 (fr)	2005-09-07	2010-12-08	Banyu Pharma Co Ltd	Dérivé de pyridone substitué aromatique bicylique
AU2006297443B2 (en)	2005-09-29	2010-08-12	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2008119687A (ru)	2005-10-21	2009-11-27	Новартис АГ (CH)	Комбинации органических соединений
AU2006307046A1 (en)	2005-10-27	2007-05-03	Msd K.K.	Novel benzoxathiin derivative
WO2007055418A1 (fr)	2005-11-10	2007-05-18	Banyu Pharmaceutical Co., Ltd.	Derive spiro aza-substitue
BRPI0710839A2 (pt) *	2006-04-06	2011-08-23	Prosidion Ltd	agonistas heterocìclicos de gpcr
EP2038256A1 (fr)	2006-05-23	2009-03-25	TransTech Pharma, Inc	6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine et son utilisation comme medicament
PT2079732E (pt)	2006-05-29	2012-02-02	High Point Pharmaceuticals Llc	3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)- piridazina, os seus sais e solvatos e a sua utilização a título de antagonista do receptor h3 de histamina
PE20080948A1 (es) *	2006-07-25	2008-09-10	Irm Llc	Derivados de imidazol como moduladores de la senda de hedgehog
AU2007300627B2 (en)	2006-09-22	2012-02-16	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (fr)	2006-09-28	2009-10-21	Banyu Pharma Co Ltd	Dérivé de diarylcétimine
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
EP2146715A4 (fr)	2007-04-11	2011-08-31	Merck Sharp & Dohme	Antagonistes du récepteur cgrp comprenant des groupes terminaux amide tertiaire, sulfamide, carbamate et urée
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (fr)	2007-06-04	2020-10-20	Kunwar Shailubhai	Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
JP5443342B2 (ja) *	2007-06-08	2014-03-19	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ピペリジン／ピペラジン誘導体
EP2014656A3 (fr)	2007-06-11	2011-08-24	High Point Pharmaceuticals, LLC	Nouveaux antagonistes d'hétéocycliques h3
EP2264026A4 (fr)	2008-03-06	2012-03-28	Msd Kk	Dérivé d'alkylaminopyridine
WO2009119726A1 (fr)	2008-03-28	2009-10-01	萬有製薬株式会社	Dérivé de diarylméthylamide à activité antagoniste sur un récepteur d'hormone concentrant la mélanine
CL2009000904A1 (es)	2008-04-21	2010-04-30	Shionogi & Co	Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
EP2328910B1 (fr)	2008-06-04	2014-08-06	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CA2727914A1 (fr)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Derive de spirodiamine-diarylcetoxime
EP3241839B1 (fr)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2010013595A1 (fr)	2008-07-30	2010-02-04	萬有製薬株式会社	Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons)–(6 chaînons)
EP2348857B1 (fr)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
PE20110852A1 (es)	2008-10-30	2011-11-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida
AU2009309037A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075068A1 (fr)	2008-12-16	2010-07-01	Schering Corporation	Dérivés de pyridopyrimidine et leurs procédés d'utilisation
EP2379562A1 (fr)	2008-12-16	2011-10-26	Schering Corporation	Dérivés de pyranone bicyclique comme agonistes du récepteur de l'acide nicotinique
US8889674B2 (en)	2009-03-05	2014-11-18	Shionogi & Co., Ltd.	Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
SG175925A1 (en)	2009-05-15	2011-12-29	Novartis Ag	Aryl pyridine as aldosterone synthase inhibitors
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
JP5728099B2 (ja)	2011-02-25	2015-06-03	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
WO2014130608A1 (fr)	2013-02-22	2014-08-28	Merck Sharp & Dohme Corp.	Composés bicycliques antidiabétiques
EP2970119B1 (fr)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
HK1220611A1 (zh)	2013-03-15	2017-05-12	Bausch Health Ireland Limited	用於治疗胃肠道病症的组成物
WO2014151206A1 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase et leurs utilisations
CN113388007A (zh)	2013-06-05	2021-09-14	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
AU2014285301A1 (en) *	2013-07-04	2016-01-21	Nippon Soda Co., Ltd.	Phenylimidazole derivative, and therapeutic medicine or preventive medicine for inflammatory disease, etc.
ES2676585T3 (es) *	2013-08-28	2018-07-23	Medivation Technologies Llc	Compuestos heterocíclicos y métodos de uso
WO2015051496A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Composés tricycliques antidiabétiques
MX389591B (es)	2014-08-29	2025-03-20	Tes Pharma S R L	INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
US10189826B2 (en)	2015-03-04	2019-01-29	Medivation Technologies Llc	Heterocyclic compounds and methods of use
WO2016141159A1 (fr)	2015-03-04	2016-09-09	Medivation Technologies, Inc.	Bloqueurs des srebp destinés à l'utilisation dans le traitement de la fibrose hépatique, le cholestérol élevé et la résistance à l'insuline
BR112019007543A2 (pt)	2016-10-14	2019-07-02	Tes Pharma S R L	inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
EP3551176A4 (fr)	2016-12-06	2020-06-24	Merck Sharp & Dohme Corp.	Composés hétérocycliques antidiabétiques
WO2018118670A1 (fr)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Composés de spirochromane antidiabétiques
EP3573957B1 (fr) *	2017-01-24	2023-04-26	Rivara, Mirko	Compositions et procédés de blocage de canaux sodiques
WO2020104456A1 (fr)	2018-11-20	2020-05-28	Tes Pharma S.R.L	Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
EP3924058B1 (fr)	2019-02-13	2026-01-07	Merck Sharp & Dohme LLC	Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
WO2020167701A1 (fr)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Agonistes du récepteur de l'orexine de type pyrrolidine
EP4010314B1 (fr)	2019-08-08	2024-02-28	Merck Sharp & Dohme LLC	Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
WO2022040070A1 (fr)	2020-08-18	2022-02-24	Merck Sharp & Dohme Corp.	Agonistes du récepteur de l'orexine de type bicycloheptane pyrrolidine
CN117915903A (zh) *	2020-12-11	2024-04-19	佛罗里达大学研究基金会公司	用于治疗神经退行性、退行性和代谢性失调的化合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3657441A (en)	1970-07-30	1972-04-18	Merck & Co Inc	Method of inhibiting the formation of phenylethanolamine n-methyl transferase with imidazoles
US4642311A (en)	1975-03-03	1987-02-10	Merck & Co., Inc.	β-adrenergic blocking imidazolylphenoxy propanolamines
IT1168008B (it)	1981-07-31	1987-05-20	Zambon Spa	Imidazol-eteri ed ester, procedimenti per prepararli e composizioni farmaceutiche che li contengono
IT1206498B (it)	1983-07-18	1989-04-27	Angeli Inst Spa	Derivati amidinici del4-fenilmidazolo 2-sostituto processi per la loro preparazione e loro uso farmaceutico.
IL83467A0 (en)	1986-08-15	1988-01-31	Fujisawa Pharmaceutical Co	Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
JP2700475B2 (ja)	1988-07-30	1998-01-21	コニカ株式会社	非線形光学材料および非線形光学素子
TW270944B (fr)	1993-05-10	1996-02-21	Shikoku Kakoki Co Ltd
EP0712847A4 (fr)	1993-08-11	1997-05-28	Nippon Soda Co	Derive d'imidazole et son procede de production, et substance anti-nuisibles
GB9507291D0 (en) *	1995-04-07	1995-05-31	Merck Sharp & Dohme	Therapeutic agents
WO1998024785A1 (fr) *	1996-12-02	1998-06-11	Fujisawa Pharmaceutical Co., Ltd.	Derives d'indole-uree presentant des proprietes d'antagonistes de 5-ht
AU744297B2 (en)	1997-07-03	2002-02-21	Neurogen Corporation	Certain diarylimidazole derivatives; a new class of NPY specific ligands
FR2772377B1 (fr) *	1997-12-12	2000-01-07	Synthelabo	Derives de 1-(1-h-imidazol-2-yl)pyrrolidines et 1-(1-h-imidazol-2-ylpiperidines), leur preparation et leur application en therapeutique
WO1999048873A1 (fr) *	1998-03-25	1999-09-30	Bristol-Myers Squibb Company	Agents anorexigenes d'imidazolone: derives acycliques i
DK1183245T3 (da)	1999-04-22	2007-09-24	Lundbeck & Co As H	Selektive NPY(Y5)-antagonister
WO2000066578A1 (fr) *	1999-04-30	2000-11-09	Pfizer Products Inc.	Composes pour le traitement de l'obesite

2000
- 2000-12-14 AR ARP000106641A patent/AR032292A1/es unknown
- 2000-12-14 CN CNB008189250A patent/CN1227236C/zh not_active Expired - Fee Related
- 2000-12-14 SK SK845-2002A patent/SK8452002A3/sk unknown
- 2000-12-14 NZ NZ519272A patent/NZ519272A/en unknown
- 2000-12-14 RU RU2002119019/04A patent/RU2002119019A/ru not_active Application Discontinuation
- 2000-12-14 TR TR2002/01568T patent/TR200201568T2/xx unknown
- 2000-12-14 HU HU0301218A patent/HUP0301218A2/hu unknown
- 2000-12-14 WO PCT/US2000/033832 patent/WO2001044201A1/fr not_active Ceased
- 2000-12-14 CA CA002393821A patent/CA2393821C/fr not_active Expired - Fee Related
- 2000-12-14 CZ CZ20022100A patent/CZ20022100A3/cs unknown
- 2000-12-14 HK HK02106766.7A patent/HK1045503A1/zh unknown
- 2000-12-14 JP JP2001544691A patent/JP4180276B2/ja not_active Expired - Fee Related
- 2000-12-14 IL IL14987200A patent/IL149872A0/xx unknown
- 2000-12-14 US US09/737,141 patent/US6444687B1/en not_active Expired - Fee Related
- 2000-12-14 BR BR0017025-9A patent/BR0017025A/pt not_active Application Discontinuation
- 2000-12-14 PL PL00356485A patent/PL356485A1/xx unknown
- 2000-12-14 AU AU22614/01A patent/AU2261401A/en not_active Abandoned
- 2000-12-14 AT AT00986362T patent/ATE303364T1/de not_active IP Right Cessation
- 2000-12-14 MX MXPA02006016A patent/MXPA02006016A/es not_active Application Discontinuation
- 2000-12-14 KR KR1020027007619A patent/KR20020062342A/ko not_active Ceased
- 2000-12-14 DE DE60022386T patent/DE60022386T2/de not_active Expired - Lifetime
- 2000-12-14 ES ES00986362T patent/ES2243337T3/es not_active Expired - Lifetime
- 2000-12-14 EP EP00986362A patent/EP1237875B1/fr not_active Expired - Lifetime
- 2000-12-15 MY MYPI20005922A patent/MY138524A/en unknown
2002
- 2002-05-30 ZA ZA200204350A patent/ZA200204350B/en unknown
- 2002-06-14 NO NO20022835A patent/NO20022835L/no not_active Application Discontinuation
- 2002-07-23 US US10/200,966 patent/US6632828B2/en not_active Expired - Fee Related
2006
- 2006-04-12 JP JP2006110338A patent/JP2006199710A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2003517479A (ja)	2003-05-27
CA2393821C (fr)	2009-05-26
AU2261401A (en)	2001-06-25
HK1045503A1 (zh)	2002-11-29
PL356485A1 (en)	2004-06-28
JP2006199710A (ja)	2006-08-03
IL149872A0 (en)	2002-11-10
HUP0301218A2 (hu)	2003-08-28
ATE303364T1 (de)	2005-09-15
CZ20022100A3 (cs)	2002-09-11
US6444687B1 (en)	2002-09-03
CN1227236C (zh)	2005-11-16
NO20022835D0 (no)	2002-06-14
DE60022386T2 (de)	2006-06-22
CA2393821A1 (fr)	2001-06-21
EP1237875A1 (fr)	2002-09-11
ZA200204350B (en)	2003-09-01
BR0017025A (pt)	2003-01-07
DE60022386D1 (de)	2005-10-06
CN1434806A (zh)	2003-08-06
JP4180276B2 (ja)	2008-11-12
US6632828B2 (en)	2003-10-14
SK8452002A3 (en)	2002-11-06
EP1237875B1 (fr)	2005-08-31
WO2001044201A1 (fr)	2001-06-21
RU2002119019A (ru)	2004-01-10
NZ519272A (en)	2004-02-27
MY138524A (en)	2009-06-30
TR200201568T2 (tr)	2002-10-21
KR20020062342A (ko)	2002-07-25
ES2243337T3 (es)	2005-12-01
US20030114465A1 (en)	2003-06-19
AR032292A1 (es)	2003-11-05
MXPA02006016A (es)	2002-12-05

Publication	Publication Date	Title
NO20022835L (no)	2002-08-16	Substituerte imidazol neuropeptid Y Y5 reseptorantagonister
ATE232200T1 (de)	2003-02-15	Neuropeptid y5-rezeptorantagonisten
DE60136562D1 (de)	2008-12-24	Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten
IL159643A0 (en)	2004-06-01	Substituted urea neuropeptide y y5 receptor antagonists
AU2001294547A1 (en)	2002-03-26	Substituted urea neuropeptide y y5 receptor antagonists
DE69921351D1 (de)	2004-11-25	4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DE69919171D1 (de)	2004-09-09	Muskarin-rezeptor antagonisten
NO20015779L (no)	2001-11-27	Bradykinin-reseptorantagonister
NO20004503L (no)	2000-10-10	Vitronectin-reseptor-antagonister
NO20016053L (no)	2001-12-11	IL-8 reseptor-antagonister
AU1908400A (en)	2000-06-19	Benzimidazole compounds that are vitronectin receptor antagonists
NO20016052L (no)	2001-12-11	IL-8-reseptor-antagonister
DK1180028T3 (da)	2007-05-21	IL-8-receptorantagonister
NO20015662D0 (no)	2001-11-20	Oralt aktive A1-adenosinreseptorantagonister
DE60106572D1 (de)	2004-11-25	IMIDAZOLVERBINDUNGEN ALS Alpha2-ADRENOREZEPTOREN ANTAGONISTEN
NO20021113D0 (no)	2002-03-06	Vitronectin-reseptor-antagonister
NO20015774L (no)	2001-11-27	IL-8 reseptorantagonister
NO20033223D0 (no)	2003-07-16	Histamin-reseptor antagonister
NO20016102L (no)	2002-02-12	IL-8 reseptorantagonister
NO20016065L (no)	2001-12-12	IL-8-reseptor-antagonister
DK1218005T3 (da)	2005-04-11	Vitronectinreptorantagonister
HK1036065A (en)	2001-12-21	Benzimidazole compounds that are vitronectin receptor antagonists
DK1131291T3 (da)	2005-02-28	4-aroyl-piperidin-CCR-3-receptorantagonister III
HK1060845A (en)	2004-08-27	Substituted urea neuropeptide y y5 receptor antagonists

Legal Events

Date	Code	Title	Description
2005-09-12	FC2A	Withdrawal, rejection or dismissal of laid open patent application